GSK 461364

Drug Profile

GSK 461364

Alternative Names: 461364; GSK-461364; GSK461364A

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Antineoplastics; Small molecules; Thiophenes
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Non-Hodgkin's-lymphoma in United Kingdom (IV, Infusion)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in United Kingdom (IV, Infusion)
  • 07 May 2007 Preclinical trials in Cancer in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top